CLL/SLL-话题@MedSci

#CLL/SLL#

10篇内容 | 1135人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2237574, encodeId=3a5a223e57425, content=<a href='/topic/show?id=2c90650e5b1' target=_blank style='color:#2F92EE;'>#泽布替尼#</a> <a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=【AJH】泽布替尼单药治疗CLL/SLL的中国多中心真实世界研究, objectType=article, longId=851563, objectId=18248515633e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230608/1686154296951_5579292.jpg, objectUrl=/article/show_article.do?id=18248515633e, replyNumber=0, likeNumber=11, createdTime=2024-11-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=18248515633e, moduleTitle=【AJH】泽布替尼单药治疗CLL/SLL的中国多中心真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18248515633e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1631094, encodeId=c29d163109490, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL, objectType=article, longId=220308, objectId=35f022030877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35f022030877, replyNumber=0, likeNumber=98, createdTime=2021-11-15, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35f022030877, moduleTitle=Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35f022030877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631093, encodeId=e95a1631093fc, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限, objectType=article, longId=212474, objectId=868f2124e4b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868f2124e4b8, replyNumber=0, likeNumber=85, createdTime=2021-06-10, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868f2124e4b8, moduleTitle=亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=868f2124e4b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631092, encodeId=bcb716310927f, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率, objectType=article, longId=204326, objectId=d24d20432640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d24d20432640, replyNumber=0, likeNumber=88, createdTime=2020-12-10, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d24d20432640, moduleTitle=ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d24d20432640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631091, encodeId=6cfc1631091fe, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=Clin Cancer Res：随访8年！依鲁替尼治疗CLL/SLL长期有效！, objectType=article, longId=198807, objectId=814719880e41, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=814719880e41, replyNumber=0, likeNumber=59, createdTime=2020-08-07, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=814719880e41, moduleTitle=Clin Cancer Res：随访8年！依鲁替尼治疗CLL/SLL长期有效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=814719880e41)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631090, encodeId=c8f916310906f, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=李建勇教授：CLL/SLL新药“喷涌”，联合方案获益更多, objectType=article, longId=186205, objectId=93c618620524, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93c618620524, replyNumber=0, likeNumber=88, createdTime=2020-01-15, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93c618620524, moduleTitle=李建勇教授：CLL/SLL新药“喷涌”，联合方案获益更多, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93c618620524)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631089, encodeId=e01b1631089d9, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL, objectType=article, longId=185326, objectId=ed2f185326f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed2f185326f5, replyNumber=0, likeNumber=79, createdTime=2019-12-29, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed2f185326f5, moduleTitle=Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed2f185326f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631088, encodeId=83ac1631088ed, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性, objectType=article, longId=176194, objectId=46cc1e6194e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46cc1e6194e7, replyNumber=0, likeNumber=69, createdTime=2019-07-27, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46cc1e6194e7, moduleTitle=Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46cc1e6194e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631087, encodeId=9075163108e93, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=Blood：Duvelisib相比奥法木单抗可显着提高RR CLL/SLL患者的无进展存活期和总体缓解率, objectType=article, longId=150556, objectId=e527150556d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e527150556d6, replyNumber=0, likeNumber=86, createdTime=2018-10-09, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e527150556d6, moduleTitle=Blood：Duvelisib相比奥法木单抗可显着提高RR CLL/SLL患者的无进展存活期和总体缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e527150556d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631086, encodeId=3a0316310864c, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=Lancet Oncol：伊布替尼联合BR与BR对比治疗rrCLL/SLL患者：随机对照双盲Ⅲ期研究, objectType=article, longId=116553, objectId=580f11655342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=580f11655342, replyNumber=0, likeNumber=83, createdTime=2017-10-19, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=580f11655342, moduleTitle=Lancet Oncol：伊布替尼联合BR与BR对比治疗rrCLL/SLL患者：随机对照双盲Ⅲ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=580f11655342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1631085, encodeId=c0c11631085f9, content=<a href='/topic/show?id=50e0485323' target=_blank style='color:#2F92EE;'>#CLL/SLL#</a>, objectTitle=复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究, objectType=article, longId=116543, objectId=2f6e116543b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f6e116543b5, replyNumber=0, likeNumber=71, createdTime=2017-10-19, rootId=0, userName=mnda, userId=32d321676246, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f6e116543b5, moduleTitle=复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f6e116543b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CLL/SLL

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#泽布替尼# #CLL/SLL#

【AJH】泽布替尼单药治疗CLL/SLL的中国多中心真实世界研究

2024-11-18发表于上海

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

Blood：采用CAR T细胞疗法(liso-cel)治疗复发性/难治性CLL/SLL

2021-11-15

hb2008ye (审核中...)

前往app查看评论内容

#CLL/SLL#

亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂用于CLL/SLL前景无限

2021-06-10

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率

2020-12-10

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

Clin Cancer Res：随访8年！依鲁替尼治疗CLL/SLL长期有效！

2020-08-07

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

李建勇教授：CLL/SLL新药“喷涌”，联合方案获益更多

2020-01-15

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL

2019-12-29

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

Blood：高选择性BTK抑制剂zanubrutinib用于CLL/SLL的活性和安全性

2019-07-27

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

Blood：Duvelisib相比奥法木单抗可显着提高RR CLL/SLL患者的无进展存活期和总体缓解率

2018-10-09

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

Lancet Oncol：伊布替尼联合BR与BR对比治疗rrCLL/SLL患者：随机对照双盲Ⅲ期研究

2017-10-19

mnda (审核中...)

前往app查看评论内容

#CLL/SLL#

复发/难治CLL/SLL患者中比较伊布替尼和利妥昔单抗：一项随机开放性Ⅲ期研究

2017-10-19

科室
- - 订阅+
  - 更多科室
工具
服务